Trial Profile
An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2018
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors Amgen
- 01 Sep 2017 Results assessing long term efficacy and safety published in the British Journal of Haematology.
- 18 Nov 2014 New trial record